我武生物：获得豚草花粉点刺液药物临床试验补充申请批准通知书

Core Viewpoint - The company Iwu Biologics (300357.SZ) has received approval for a supplemental application for clinical trials of its drug "Ragweed Pollen Skin Prick Solution," which is aimed at diagnosing type I hypersensitivity diseases related to ragweed pollen allergy [1] Group 1 - The drug is classified as a therapeutic biological product and is formulated as a skin prick reagent [1] - The approved formulation has a total allergen activity of 3500 DU/ml and comes in a 2 ml bottle [1] - The company will fulfill its information disclosure obligations based on the progress of the clinical trials [1]